U.S. Markets closed

Tesaro, Inc. (TSRO)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
118.86+5.00 (+4.39%)
At close: 4:00PM EDT

118.52 -0.34 (-0.29%)
After hours: 4:54PM EDT

People also watch
CLVSPBYIKITEPTLAAGIO
Full screen
Previous Close113.86
Open113.15
Bid118.86 x 100
Ask175.00 x 400
Day's Range113.12 - 119.46
52 Week Range83.26 - 192.94
Volume1,393,334
Avg. Volume1,286,506
Market Cap6.4B
Beta2.20
PE Ratio (TTM)-13.95
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com3 days ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com3 days ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.34 billion over the last one-month.